Cancer Discovery of novel hydrophobic tag degraders of ALK fusion protein Feb. 23, 2023 Targeted protein degradation (TPD) has emerged as a therapeutic strategy to overcome intractable disease-causing proteins, and hydrophobic...Read More
Cancer Novel KRAS(G12C) inhibitor shows efficacy in models of KRAS-mutant NSCLC Dec. 30, 2022 Researchers from Nanjing University and China Pharmaceutical University have reported the discovery and preclinical evaluation of a novel KRAS(G12C) inhibitor.Read More
